Abstract
Multiple sclerosis (MS) as a chronic disease presents a vast variability of neurological symptoms. Spasticity is one of the most common symptoms. The principle indication to treat spasticity is disability or handicap of capabilities. All pharmacological methods are attributed to a basic physical management. Different effective treatment schemes have been established. Nevertheless the value of intrathecal triamcinolone acetonid (TCA) in MS is still a controversial issue. Bearing in mind that only limited data are available and due to its invasive application form repeated TCA administration can be recommended as one therapy option in MS with a progressive clinical course and predominantly spinal symptoms.
Keywords: Multiple sclerosis, intrathecal steroids, triamcinolone acetonide, spasticity, neurological symptoms, inflammatory disease, neuron, methylprednisolone acetate (MPA), steroids, intrathecal.
Current Pharmaceutical Design
Title:Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Volume: 18 Issue: 29
Author(s): Mazen Abu-Mugheisib, Reiner Benecke and Uwe K. Zettl
Affiliation:
Keywords: Multiple sclerosis, intrathecal steroids, triamcinolone acetonide, spasticity, neurological symptoms, inflammatory disease, neuron, methylprednisolone acetate (MPA), steroids, intrathecal.
Abstract: Multiple sclerosis (MS) as a chronic disease presents a vast variability of neurological symptoms. Spasticity is one of the most common symptoms. The principle indication to treat spasticity is disability or handicap of capabilities. All pharmacological methods are attributed to a basic physical management. Different effective treatment schemes have been established. Nevertheless the value of intrathecal triamcinolone acetonid (TCA) in MS is still a controversial issue. Bearing in mind that only limited data are available and due to its invasive application form repeated TCA administration can be recommended as one therapy option in MS with a progressive clinical course and predominantly spinal symptoms.
Export Options
About this article
Cite this article as:
Abu-Mugheisib Mazen, Benecke Reiner and K. Zettl Uwe, Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502251
DOI https://dx.doi.org/10.2174/138161212802502251 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Antimicrobial and Antifungal Properties of Leaves to Root Extracts and Saponin Fractions of <i>Chlorophytum borivilianum</i>
Current Bioactive Compounds COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects
Current Medicinal Chemistry Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology HPLC-DAD-Q-TOF/MS-Based Screening and Analysis of the Multiple Absorbed Bioactive Components in Rat Serum after Oral Administration of Xiexin Tang
Current Pharmaceutical Analysis Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets The Importance of Precise Documentation of Vaccination by Physicians and Vaccine Providers
Current Drug Safety Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice Primary Neurons
Current Molecular Medicine Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Cancer-Homing Toxins
Current Pharmaceutical Design Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines
Current Topics in Medicinal Chemistry